Related Experiment Video
Updated: Jul 16, 2026
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Orbital metastasis of prostate cancer: a case report
Nihat Uluocak1, Bekir Suha Parlaktas, Fatih Ersay Deniz
1Department of Urology, Gaziosmanpasa University, Tokat, Turkey.
Abstract:
We report a case with metastatic orbital cancer secondary to prostatic adenocarcinoma. After initiation of total androgen blockade, the visual complaints, pain and periorbital swelling regressed dramatically within 2 months of treatment. However, the disease subsequently progressed and the patient died 12 months after diagnosis.
Insights
Metastatic orbital cancer from prostate cancer initially responded well to androgen blockade therapy, improving vision and reducing swelling. However, the cancer eventually progressed, leading to patient death within a year.
Area of Science:
- Oncology
- Ophthalmology
- Urology
Background:
- Prostatic adenocarcinoma is a common cancer in men.
- Orbital metastases are rare but can significantly impact patient quality of life.
Observation:
- A patient presented with orbital cancer secondary to known prostatic adenocarcinoma.
- Symptoms included visual complaints, pain, and periorbital swelling.
Findings:
- Total androgen blockade therapy led to rapid regression of orbital tumor symptoms within two months.
- Despite initial response, the metastatic prostate cancer progressed subsequently.
Implications:
- Androgen blockade can provide temporary palliation for orbital metastases of prostate cancer.
- This case highlights the aggressive nature of some metastatic prostate adenocarcinomas.
- Further research into novel therapeutic strategies for advanced prostate cancer with orbital involvement is warranted.
